Quickly metabolized and excreted through the kidneys. It is metabolized similar to endogenous purine nucleotides with the formation of uric acid. NN-dimethylamino-2-propranolon metabolized to N-oxide and the steam-to-atsetamidobenzoat atsilglyukuronida -up. Not detected drug accumulation in the body. The half-life is 3.5 hours for the NN-dimethylamino-2-propranolona masteron steroids and 50 minutes-for para-atsetamidobenzoata. The elimination of the drug and its metabolites are excreted occurs within 24-48 hours.
Treatment of influenza and other acute respiratory viral infections,
– infections caused by Herpes simplex virus 1 st, 2 nd, 3 rd and 4 th type: genital and labial herpes, herpetic keratitis, herpes zoster, chickenpox, infectious mononucleosis caused by a virus Epstein-Barr virus;
– cytomegalovirus infection;
– heavy current measles;
– human papillomavirus infection: laryngeal papilloma / vocal cords (the fibrous type), genital HPV infection in men and women, warts
– molluscum contagiosum.
– Hypersensitivity to the drug;
– chronic renal failure;
– children up to 3 years (weight 15-20 kg).
Use of the drug during pregnancy and lactation
Do not use the drug during pregnancy and lactation, as safety of use has not been studied.
Dosing and Administration
The tablets are taken orally after meal with a little water.
The recommended dose for adults and children from 3 years old (body weight of 15-20 kg) is 50 mg / kg per day, divided into 3-4 receptions. Adults – 6.8 tablets per day, children – 2.1 tablets per 5 kg / body weight per day. In severe infections the dose may be increased individually to 100 mg / kg of body weight per day, divided into 4-6 doses. The maximum daily dose for adults 3-4 g / day, for children – 50 mg / kg / day.
Duration of treatment:
Acute disease: the duration of treatment in adults and children is usually 5 to 14 days. The treatment should continue until the disappearance of clinical symptoms and for a further 2 days, even at the absence of symptoms. If necessary, the duration of treatment can be increased individually supervised by a doctor.
In chronic recurrent diseases in adults and children, treatment should continue for several courses of 5-10 days with a break in reception in 8 days.
For maintenance therapy dose can be reduced to 500-1000 mg per day (1-2 tablets) for 30 days.
When herpes infection masteron steroids in adults and children is prescribed for 5-10 days before the disappearance of disease symptoms, asymptomatic period – 1 tablet 2 times a day for 30 days to reduce the number of relapses.
When infection papilomavirusnoy adult drug administered 2 tablets 3 times a day for children – 1/2 . Tablets of 5 kg / body weight per day in 3-4 divided doses for 14-28 days as monotherapy.
With recurrent genital warts adult drug administered 2 tablets 3 times children – 1.2 tablets per 5 kg / body weight per day in 3-4 divided doses a day or as monotherapy or in combination with surgery for 14-28 days, followed by a triple repetition of this course at intervals of 1 month. When cervical dysplasia, associated with human papilloma virus, administered 2 tablets 3 times a day for 10 days, then spend 2-3 similar course with an interval of 10-14 days.
The incidence of side effects after the drug is classified according to WHO recommendations.
Often:> = 1% and <10%.
Sometimes:> = 0.1% and <1%.
From the gastrointestinal tract: often – nausea, vomiting, epigastric pain, sometimes – diarrhea, constipation.
Of the liver and biliary tract: often masteron steroids – a temporary increase in transaminases and alkaline phosphatase activity in plasma, increasing the concentration of urea in plasma.
Skin and subcutaneous tissue: often – itching.
From the nervous system: often – headache, dizziness, weakness; sometimes, drowsiness, insomnia.
From the mochevydelitelnoy system: sometimes – polyuria.
On the part of the musculoskeletal system and connective tissue disorders: often – joint pain, worsening of gout.
Cases of overdose have not been described.
Interaction with other drugs
Immunosuppressive drugs may reduce the effectiveness of the drug. Xanthine oxidase inhibitors and uricosuric drugs (including diuretics) may contribute to the risk of high levels of uric acid in the blood serum of patients taking Isoprinosine.
After 2 weeks of use izoprinozin should be undertaken to control the concentration of uric acid in the serum and urine.
Chronic administration after 4 weeks of application it is advisable to carry out monthly monitoring of liver and kidney function (transaminase activity in blood plasma, creatinine, uric acid).
It is necessary to control the level of uric acid in blood serum when assigning Isoprinosine in combination with drugs that increase the levels of uric acid ilipreparatami violating kidney function.
Effects on ability to drive vehicles and other mechanisms
No specific contraindications.
Tablets mg.10 500 tablets per blister PVC / PVDC and aluminum foil.
2, 3, or 5 in blister pack carton along with instructions for use.
Do not use after the date printed on the packaging.
List B. Store at temperatures above +25 ° C in a dry, dark place. Keep out of the reach of children.
Conditions of supply